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See Article, pages 479–487All too frequent we physicians ignore ‘‘primum non nocere’’ (ﬁrst
do not harm), and believe all too frequently treatment is always
the answer. Once we have treatments available, we frequently
believe that the worst which can happen is the failure of treat-
ment, ignoring that side effects might be more than a mere nui-
sance. Even a supposedly safe treatment such as lamivudine was
demonstrated to be lethal in very special individuals with certain
viral resistance mutations, when lamivudine was not stopped in
time [1]. In contrast to lamivudine and other oral antivirals for
hepatitis B, which extremely rarely cause adverse events and
seem to have a safety proﬁle similar to placebo [2,3], the current
therapy of hepatitis C is both less safe and not effective in
everyone.
Interferon has been the backbone of HCV therapy for more
than 20 years, but likely will remain a crucial component of
HCV treatment regimens only for a few more years.
In the early nineties, only about 5 to 10% of patients sustained
normalization of liver enzymes with/without sustained viral
response (SVR) after 24 weeks of therapy [4], and still remained
below 20% when extended to 48 weeks. A signiﬁcant improve-
ment was the addition of ribavirin, leading to a signiﬁcantly
and clinically meaningful increase in the rate of SVR, but also
to more side effects [5,6].
The modiﬁcation of the standard interferon molecule by cou-
pling interferon with a polyethylene glycol (PEG) improved the
success rates, but did not improve the overall safety proﬁle of
HCV targeted therapy, and might have further increased side
effects [7,8]. Interestingly, all randomized studies comparing
pegylated interferon-a2a to -a2b showed a slight and sometimes
signiﬁcant advantage for PegIFN-a2a [9]. Of note, even the largest
trial sponsored by Schering-Plough and producer of PegIFN-a2b
demonstrated a 1% difference in favor of PegIFN-a2a [10]. How-
ever, while the efﬁcacy was seen to be slightly higher with
PegIFN-a2a, the risk of death and serious adverse events (SAE)
was likewise slightly higher, suggesting there is indeed ‘‘no such
thing as a free lunch’’. A meta-analysis reported 50 deaths in
14,401 patients treated with a PegIFN-a2a containing regimens
(0.18% or 1 in 288 patients [95%CI: 0.13–0.24%]) compared to 16Journal of Hepatology 20
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regimens (0.058% or 1 in 823 [95% CI: 0.033–0.094%]) [11]. Note
that the conﬁdence intervals do not overlap, suggesting statistical
signiﬁcant difference in the epidemiologic aspect. Similar results
were observed for higher SAE rates in patients receiving regimens
containing PegIFN alpha-2a than in those with PegIFN alpha-2b
(7.45 vs. 6.74 %). This analysis also suggested that the risk of an
SAEmight be lowerwith lower doses and shorter duration of ther-
apy. For either PegIFN lower rates of SAEwere observedwith stan-
dard 48-week therapy versus extended duration therapy 6.67%
versus 15.5% (sixteen (0.058%; 95% CI 0.033–0.094%) patients).
Therefore, pre-treatment predictors and on treatment predic-
tion of response became crucial: HCV genotype (2-3-4-1 best to
worst response), ethnicity (Asians responding best and African
Americans the worst, Caucasians and Hispanics in-between),
low HCV baseline viral load, younger age, histology (low ﬁbrosis
and little or no steatosis), low GGT levels, and more recently
IL28B genotype were identiﬁed as crucial predictors [8,12,13].
However, only the viral load decline at week 12 would sufﬁ-
ciently distinguish a non-responder from a potential responder
[9], to modify treatment with negative predictive value.
It was interesting though to note that results for prediction
response based on earlier time points than the week 12 results
have never been published, until an alternative long-acting inter-
feron coupled to albumin was developed. In that study it was
demonstrated that the eventual response or non-response,
respectively, could be predicted as early as week 2 in some and
at week 4 in others, demonstrating that <1 log at week 4 is sim-
ilar in predicting eventual failure to achieve SVR as <2 log at week
12 [14]; thus, enabling to spare patients from another 8 weeks of
potential harmful therapy.
From the licensing of pegylated interferon, it took about a dec-
ade until a newer more effective therapy became available in
form of the two currently licensed protease inhibitors: boceprevir
and telaprevir [15–18]. These treatments have increase SVR rates
by roughly 30%.
As with most of the previous improvements in therapy for
HCV, either of these protease inhibitors currently licensed, boce-
previr and telaprevir, signiﬁcantly increase rate and severity of
adverse events. Though each has distinct side effects, the major
concerns are potential fatalities. Thus, for now higher efﬁcacy is
gained at the cost of more and potentially fatal side effects [20].13 vol. 58 j 412–414
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Initially there was a dilemma, how to triage all those patients
now in line to be treated [19]. However, quickly after the licens-
ing of the protease inhibitors, amazing data suggesting much eas-
ier regimens with even higher success rates are emerging, since
autumn 2011, with expected licensing of an easier treatment as
early as 2014. The rapid development of direct antiviral agents
(DAA) for HCV led Jean Michel Pawlotsky to pronounce, in his
summary of ‘‘The International Liver Meeting’’ in April 2012,
the foreseeable ‘‘death of interferon’’.
Interestingly, with each improvement of efﬁcacy concerning
HCV clearance, treatments have increased in side effects so far,
but that is likely to change with the next round of DAA to be
licensed in the near future.
Thus, the major clinical question facing physicians caring for
patients with advanced ﬁbrosis in 2013 will be: does the patient
need treatment now or is there time to await the very promising
newer treatments, and to consider what can be a downside of
treatment now?
One concern with unsuccessful therapy is the development of
resistance, which can occur against both an antiviral and against
interferon. There is no question that antivirals select formutations
associated with resistance [21], and mathematical modelling sug-
gests that resistance development might be successfully be over-
come, when a treatment regimen would require 4 or more
mutations to lose its effect [22]. Interferon resistance is less
accepted, but there are several lines of evidence: in vitro cells
can acquire resistance towards interferon when conditioned with
interferon [23,24]. This phenomenon can explain why some
patients showed less decline of viral load with subsequent
improved treatments from standard IFN to pegylated interferon
with ribavirin, with each improved treatment viral load decline
should have been steeper than in a previous less effective therapy.
However, in several patients a less steep decline is observed in
subsequent therapies, compatible with resistance to interferon.
Secondary, the concept of interferon resistance would be sup-
ported by the data that previously treated patients also respond
less to a subsequent treatment with direct antiviral, such as the
data presented for ABT-450/R+ABT-333 and GS-7977, respec-
tively, in treatment naïve versus treatment experienced patients
[25,26].
Thus, patients with mild to moderate disease (Stage 0 to 2)
should most likely be advised to await the newer options, as
we likely will see treatments emerging which are effective in
almost everyone, with fewer side effects than current treatment.
In contrast, patients with advanced ﬁbrosis (F3) and more so
with cirrhosis (F4) will be those with the greatest need for treat-
ment rather sooner than later. Unfortunately, this patient popula-
tion is usually under-represented in most HCV clinical trials.
The analysis presented in this issue of the Journal of Hepatol-
ogy highlights the speciﬁc information for that population of
patients with advanced ﬁbrosis [27]. Though clearly an individual
study would be preferential, the retrospective analysis, reported
in this issue of the Journal, still gives important additional infor-
mation. This analysis also gives a clear example of the shortcom-
ing of the small sample size in post hoc analysis, as a higher SVR
rate is reported in patients with cirrhosis randomized to the
PegIFN RBV arm (6/13, 46%) versus those randomized to PegIFN
RBV plus boceprevir arms (5/16, 31% in the response guided ther-
apy arm, and 10/24, 41% in the ﬁxed 48-week therapy arm).
Importantly, patients showing <1 log decline during the ‘‘lead-
in’’ with PegIFN had low SVR even in the BOC containing armsJournal of Hepatology 201with 11–33% for F3 and 10–14% for F4, versus 69% to 89% SVR
in those achievingP1 log decline by week 4. Thus, for those fail-
ing to achieve 1 log decline by week 4 in the lead-in period, there
was only a low chance to achieve SVR by adding boceprevir.
Because of the numbers in each of the group are small, the pre-
diction has high uncertainty, but certainly warrants critical con-
sideration of risk–beneﬁt ratio. In the subgroup of patients with
a baseline viral load >2,000,000 IU/ml, the failure to achieve 1
log reduction resulted in a 94% negative predictive value for
achieving SVR; thus giving a relative clear indication to stop ther-
apy if the 1 log decline margin is not crossed [15].
In a similar study with telaprevir, it was likewise seen that
patients with P1 log decline tended to more likely achieve SVR
than those with 1 log decline, during a 4-week ‘‘lead-in’’ period
with peginterferon and ribavirin. This difference between those
with P1 log versus those with 1 log decline was only signiﬁcant
in the previous null-responders with 54% vs. 15%, while the dif-
ference was 59% vs. 56% in partial responders (which would be
more likely non-responders in the boceprevir study) and 90%
vs. 60% in previous relapsers, and overall 90% vs. 33% for >1 log
versus <1 log in a 4-week ‘‘lead-in’’ with PegIFN and ribavirin
[28]. In that study, 40 to 50% of patients had advanced ﬁbrosis,
but no separate analysis for F3 and/or F4 ﬁbrosis was given in
the telaprevir study. This could potentially suggest that for partial
responders with P1 log decline, boceprevir might be the better
choice, while telaprevir might be the better choice for those with
less than 1 log decline. Importantly, there is no head to head
study and numbers are too small to gain small conﬁdence inter-
vals to be conﬁdent.
In both these recent analyses, about 2/3 of F3/F4 patients with
prior relapse or partial response/non-response achieve more than
1 log decline at week 4, which resulted in very good SVR rates of
about 80%.
For a 4-week ‘‘lead-in’’ study with PegIFN and ribavirin, prior
to adding telaprevir, only a less than 2 log decline at week 12 was
highly predictive of failure to achieve SVR [26].
Will IL28B remain relevant with treatments getting more
effective and approaching 100%?
Scientiﬁcally? Yes! Some interferon-free studies still found a
role for IL28B with a direct antiviral alone. Patients with beneﬁ-
cial IL28B genotype might be more likely to qualify for shortened
treatment duration, but if such shortened durations are indeed
best managed by IL28B or better by on treatment response
remains to be determined.
Clinically? Likely not! The importance of IL28B in protease
inhibitor plus PegIFN and ribavirin therapy was smaller than in
PegIFN plus ribavirin. IL28B is already less likely to determine
to start current triple therapy due to the relative high chance of
SVR, even in patients with less favorable IL28B genotypes. Fur-
thermore, on treatment response will likely be more important
than a pretreatment predictor. In that regard, it is worth noting
that in the retrospective analysis of the pivotal boceprevir studies
(SPRINT-2, and RESPOND-2) presented in this issue, viral load
reduction by more than 1 log at week 4 was the strongest predic-
tor of SVR achievement.
However, with treatment durations approaching a total of
4 weeks, the time point to determine virological on treatment
response will be required to be as early as at day 2 or 3 of therapy.
Will we truly cure HCV in 4 weeks? Given the horizon of
development in HCV about a decade ago, I predicted in 2005, that
in 10 years from then, we will be able to cure HCV in 4 weeks.3 vol. 58 j 412–414 413
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This would contradict the mathematical modeling from 2011 that
suggested that 7 to 10 weeks would be the minimal duration
[29]. However, there are no data to model on what happens
between the virus becoming undetectable and when the last
virus is eliminated from the body. We have seen already 14 out
of 14 patients being negative at SVR4, in a 6-week regimen [30].
Though the treatment duration for the future is still evolving,
the close to 100% SVR rate appears to approach reality within
the next 3 years, at least for treatment naïve patients. However,
cirrhotic patients likely will remain more difﬁcult to treat, and
therefore, inclusion of a substantial proportion of cirrhotic
patients into ongoing and future phase III studies would be crucial
to assess safety and efﬁcacy of newer DAAs in cirrhotic patients.Conﬂict of interest
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